secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0002007919-24-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx Biosciences reports $1.9B net income in Q2 2024 after separation from former parent
--------------------------------------------------------------------------------

- Net income of $1.9 billion for Q2 2024, compared to net loss of $47.1 million in Q2 2023
- Cash and cash equivalents $226.9M as of June 30, 2024, down from $255.4M at May 30 separation
- Separation from Inhibrx, Inc. completed May 30: INBRX-101 transferred to Sanofi for ~$2.2B
- Stockholders received $30 cash per share, one $5 CVR, and one Inhibrx Biosciences share per four former parent shares

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791924000031/0002007919-24-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791924000031/inhibrx-20240813.htm
  HTML page:      https://secwatch.observer/filing/0002007919-24-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer